<DOC>
	<DOCNO>NCT02583919</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability ISIS-GCGRRx combination metformin versus placebo</brief_summary>
	<brief_title>Safety , Tolerability Efficacy ISIS-GCGRRx Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female , age 18 75 BMI ≥ 25.0 kg/m2 HbA1c ≥ 8.0 % ≤ 10.5 % Type 2 Diabetes Mellitus stable dose Metformin Agree conduct homebased ( fast ) blood glucose test direct Clinically significant abnormality medical history physical exam Show evidence uncorrected hypothyroidism hyperthyroidism hormone result History solid organ transplant renal dialysis History liver disease History great 3 episode severe hypoglycemia within 6 month screen Treatment antidiabetic drug ( ) metformin within 3 month screen History diabetic ketoacidosis Any significant illness condition may interfere patient participate complete study Inability unwillingness comply protocol study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>